News
Experience with 20% subcutaneous immunoglobulin in the treatment of primary immunodeficiency
Patients with primary antibody deficiency are administered immunoglobulin (Ig) replacement therapy to prevent recurrent infections. An open-label phase III study evaluated the efficacy and safety of a 20% IgG solution for subcutaneous administration compared to a 10% solution administered intravenously. We offer a brief summary of its results.
The Benefit of Liposomal Irinotecan in the Treatment of Pancreatic Cancer in a Young Patient – A Case Study
Pancreatic tumors continue to be a challenge in modern oncology. Due to the asymptomatic nature of…
Each Missed Dose of Thromboprophylaxis in Trauma Patients Significantly Increases the Risk of VTE
Available data shows that enoxaparin prophylaxis effectively reduces the incidence of venous thromboembolism...
Biosimilars in the Prophylaxis of Venous Thromboembolism
Hospitalized patients with internal diseases or after surgery have an increased risk of venous thromboembolism...
46th annual European Hernia Society conference 2024
The 46th EHS annual conference 2024, held at the Prague Congress Centre from 29th to 31st May 2024,…
Technology allows children in palliative care to escape from the hospital room for a while
Children's palliative care is a field that is just developing in our country. Palliative teams are…
With MD Eva Drbohlavová on Innovations in the Treatment of von Willebrand Disease and Improving Patients' Quality of Life
Von Willebrand Disease (vWD), as the most common congenital bleeding disorder, remains…
Artificial Intelligence Helps Dentists Find Cavities or Create Implants
Just like in other fields of medicine, artificial intelligence (AI) has been experiencing a…
The Role of Inflammation in the Cardiovascular Continuum and the Aging Process
Inflammation plays a role at various stages of the cardiovascular (CV) continuum, in both…
Subcutaneous vs. Intravenous Immunoglobulins in Patients with CLL
Secondary antibody immunodeficiency is a common complication in patients with chronic lymphocytic…